Originally approved for managing type 2 diabetes, semaglutide has demonstrated significant weight loss benefits in clinical trials, with some patients losing 10-15% of their body weight over 68 weeks
If you're looking for added support while working toward your health goals, this could be a great next step
Chemical irritation from the medication formulation itself may contribute to localized skin reactions
Lillys Triple Agonist Retatrutide Delivered Weight Loss of Up to an Average of 71.2 lbs in TRIUMPH-4 Phase 3 Trial
Excess adipose tissue is associated with chronic, low-grade inflammation, insulin resistance, abnormal cholesterol levels, high blood pressure and metabolic syndrome, all of which are associated with increased risk of heart disease and stroke
Some patients decide to switch to less expensive but less effective medications